Improving the Standard of Care for Solid Tumor Cancers

Improving Patient
Outcomes in
Solid Tumor
Cancer Treatment

BIO300
A New Class of Cancer Drug
COVID-19

BIO300
Preventing long term lung damage caused by inflammation
Keeping America Safe

BIO300
Protecting Civilians, First Responders and Our Military
from Nuclear Accidents and Terrorism

BIO 300 improves outcomes for cancer patients receiving radiation treatments.

BIO 300 limits inflammation and fibrosis caused by viral infections and other pulmonary injuries.

BIO 300 prevents and mitigates acute and delayed radiation injuries from nuclear accidents or acts of terrorism.

Humanetics News

US Department of Defense Awards $5.1 Million to Humanetics for Continued Development of Radiation Countermeasure
Read More

Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites
Read More

Humanetics Corporation Publishes New Data Comparing BIO 300 with Neulasta
Read More

Humanetics Corporation Appoints Mr. Douglas W. Bryce to its Board of Advisors
Read More

Humanetics Corporation Adds Two New Experts to its Board of Directors
Read More

Humanetics Corporation Completes Phase 1 Trial
Read More

Humanetics Corporation's BIO 300 Receives Fast Track Designation from FDA
Read More

Humanetics Corporation Receives Funding from Regenerative Medicine Minnesota to Study New Drug for Triple Negative Breast Cancer
Read More

Humanetics Corporation Receives Funding from Department of Defense to Test Drug Against COVID-19
Read More